Magic mushroom drug tested to lift spirits in devastating ALS
NCT ID NCT06656702
Summary
This early-stage study is exploring whether psilocybin, the active compound in 'magic mushrooms,' can help treat depression in people with ALS (Lou Gehrig's disease). Researchers at Johns Hopkins will give up to 24 participants with ALS and depression two guided psilocybin sessions over 8 weeks. The main goal is to see if this treatment approach is practical and safe for this patient group, while also checking if it improves mood, hopelessness, and quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins Center for Psychedelic and Consciousness Research
RECRUITINGBaltimore, Maryland, 21224, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.